Format

Send to

Choose Destination
CNS Oncol. 2014;3(5):337-48. doi: 10.2217/cns.14.37.

Diffuse intrinsic pontine glioma: time for therapeutic optimism.

Author information

1
Pediatric Neuro-Oncology, Department of Pediatrics, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 87, Houston, TX 77030, USA.

Abstract

Diffuse intrinsic pontine glioma (DIPG) is an aggressive tumor that is universally fatal, and to-date we are at a virtual standstill in improving its grim prognosis. Dearth of tissue due to rarity of biopsy has precluded understanding the elusive biology and frustration continues in reproducing faithful animal models for translational research. Furthermore the intricate anatomy of the pons has forestalled locoregional therapy and drug penetration. Over the last few years, biopsy-driven targeted therapy, development of vitro and xenograft animal models for therapeutic testing, profiling immunotherapeutic strategies and locoregional infusion of drugs in brain stem tumors, now provide a sense of hope in the years ahead. This review aims to discuss current status and advances in the management of these tumors.

KEYWORDS:

oncogenic drivers; pontine glioma; signaling pathways; targeted therapy; tumor heterogenity

PMID:
25363006
DOI:
10.2217/cns.14.37
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center